• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

    2/14/23 8:25:43 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email
    SC 13G/A 1 deeptrack-ardx123122a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    ARDELYX, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    039697107

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  039697107
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Capital, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  039697107
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Biotechnology Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    CO

     


     

    CUSIP No.  039697107
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    David Kroin
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC
     


     

     

    CUSIP No. 039697107
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    ARDELYX, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    400 Fifth Avenue, Suite 210

    Waltham, Massachusetts 02451

    Item 2.(a) Names of Persons Filing:

    (i) Deep Track Capital, LP

    (ii) Deep Track Biotechnology Master Fund, Ltd.

    (iii) David Kroin 

      

    Item 2.( b) Address of Principal Business Office:

    (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

    (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands

    (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

      

    Item 2.(c) Citizenship:

    (i) Delaware

    (ii) Cayman Islands

    (iii) United States

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    039697107

     

    CUSIP No.  039697107
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

     

     

     

     

    CUSIP No. 039697107
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2022, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on 187,459,645 Common Stock outstanding.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 039697107
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
     
    CUSIP No. 039697107
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
    Get the next $ARDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDX

    DatePrice TargetRatingAnalyst
    6/18/2025$10.00Buy
    H.C. Wainwright
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    4/5/2024$14.00Outperform
    Leerink Partners
    12/18/2023$12.00Strong Buy
    Raymond James
    More analyst ratings

    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ardelyx Announces Changes to the Executive Leadership Team

    Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs today announced changes to the Executive Leadership Team. The company announced the appointment of Edward Conner, M.D. to the position of Chief Medical Officer. Dr. Conner is a seasoned biopharmaceutical executive with more than two de

    8/4/25 4:08:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

    Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million Company ends Q2 with $238.5 million in cash, cash equivalents and investments Company raises 2025 IBSRELA net sales revenue expectations to $250-$260 million Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant u

    8/4/25 4:01:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

    WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under th

    7/21/25 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Ardelyx with a new price target

    H.C. Wainwright resumed coverage of Ardelyx with a rating of Buy and set a new price target of $10.00

    6/18/25 7:56:36 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx downgraded by Raymond James with a new price target

    Raymond James downgraded Ardelyx from Strong Buy to Outperform and set a new price target of $11.00

    5/2/25 8:06:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann resumed coverage on Ardelyx

    Ladenburg Thalmann resumed coverage of Ardelyx with a rating of Buy

    3/7/25 8:02:22 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bazemore Robert B was granted 41,551 shares (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/23/25 8:44:06 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rodgers Richard J was granted 63,019 shares, increasing direct ownership by 18% to 413,543 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/23/25 8:42:03 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parsey Merdad was granted 15,235 shares, increasing direct ownership by 36% to 57,291 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/23/25 8:41:17 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.

    SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)

    8/14/25 11:34:57 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Ardelyx Inc.

    10-Q - ARDELYX, INC. (0001437402) (Filer)

    8/4/25 4:41:51 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ARDELYX, INC. (0001437402) (Filer)

    8/4/25 4:22:58 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $725,880 worth of shares (200,000 units at $3.63), increasing direct ownership by 7% to 2,896,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/18/25 9:28:07 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $737,260 worth of shares (200,000 units at $3.69), increasing direct ownership by 8% to 2,696,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/11/25 9:40:28 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $329,120 worth of shares (100,000 units at $3.29), increasing direct ownership by 4% to 2,496,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    5/19/25 5:02:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    7/10/24 6:32:11 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    2/13/24 5:26:59 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Announces Changes to the Executive Leadership Team

    Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs today announced changes to the Executive Leadership Team. The company announced the appointment of Edward Conner, M.D. to the position of Chief Medical Officer. Dr. Conner is a seasoned biopharmaceutical executive with more than two de

    8/4/25 4:08:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

    WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and Strategy, has been promoted to Chief Business Officer, and James P. Brady has joined the company as Chief Human Resources Officer. Since joining Ardelyx in March 2024, Mr. Kelliher has established himself as important leader driving Ardelyx's long-term growth and value creation strategies. In his newly expanded role as Chief Business Officer, Mr.

    6/2/25 4:05:01 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

    WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

    4/29/25 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Financials

    Live finance-specific insights

    View All

    Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

    Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million Company ends Q2 with $238.5 million in cash, cash equivalents and investments Company raises 2025 IBSRELA net sales revenue expectations to $250-$260 million Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant u

    8/4/25 4:01:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

    WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under th

    7/21/25 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

    Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

    5/1/25 4:01:51 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care